Pre-made Cadonilimab biosimilar ( Bispecific Mixed mAb and scFv, anti-PDCD1;CTLA4 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-088
Anti-PDCD1;CTLA4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cadonilimab (AK104) is a novel, potential next-generation,first-in-classbi-specificPD-1/CTLA-4immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDCD1;CTLA4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv)|
|Format||Bispecific Mixed mAb and scFv|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma|